Clene Inc (CLNN) - News Archive

Clene Inc. Secures $7.3 Million Through Direct Offering and Strategic Private Placements to Bolster Financial Position Amidst Growth in Neurological Treatment MarketIn a compelling strategic move, Clene Inc. (Nasdaq: CL...

In a significant development for Clene Inc. (Nasdaq: CLNN), the company announced on September 30, 2024, that it entered into a securities purchase agreement with a healthcare-focused institutional investor. This deal e...

Clene Inc. Taps into Potential ALS Breakthrough with FDA In-Person Meeting on CNM-Au8 DevelopmentIn a significant development for neurodegenerative disease treatment, Clene Inc. (Nasdaq: CLNN), along with its wholly own...

Clene Inc. Advances ALS Treatment with Promising Phase 2 Clinical Data Submission to FDA In a significant advance in the fight against amyotrophic lateral sclerosis (ALS), Clene Inc. (Nasdaq: CLNN) reported the submissi...

In recent months, Clene Inc shares have been trailing the overall market performance, lacking the 18.18% growth seen across the market. This article aims to analyze the events surrounding Clene Inc and explore the impli...

Clene Inc. and its subsidiary Clene Nanomedicine Inc. have recently announced plans to submit a briefing book to the U.S. Food and Drug Administration (FDA) in connection with a granted Type C interaction. The purpose o...

SALT LAKE CITY, July 09, 2024 Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company specializing in improving mitochondrial health and protecting neuronal function for the treatment of neurodegenerative...

Rett Syndrome is a rare, debilitating neurodevelopmental disorder that predominantly affects girls. It is caused by a mutation in the MECP2 gene, resulting in severe behavioral and physical symptoms. Currently, there ar...

Clene Inc. Unveils Promising Data from CNM-Au8 at ENCALS 2024, Celebrating Key Milestones and Future Directions Clene Inc. (Nasdaq: CLNN), along with its wholly owned subsidiary Clene Nanomedicine Inc., continues to for...

Clene s CNM-Au8 Shows Promising Results in ALS Treatment as NIH-funded Expanded Access Program Progresses SALT LAKE CITY, May 28, 2024 - Clene Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine Inc., have announ...

In a recent episode of the podcast From Lab to Launch, Rob Etherington, President, Director, and CEO of Clene Inc., explores the inspiring journey of his late-stage biopharmaceutical company. The discussion delves into...

In a recent press release, IBN, a renowned communications organization specializing in connecting public companies with the investment community, announced the participation of Rob Etherington, the President, Director,...

Clene Inc. and its subsidiary, Clene Nanomedicine Inc., have presented clinical results from two long-term extension trials highlighting the potential of CNM-Au8, a novel drug compound aimed at improving mitochondrial h...

Clene Inc., a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and safeguarding neuronal function for the treatment of neurodegenerative diseases, including amyotrophic lateral sclero...

Clene Reports Promising Results in the Treatment of ALS with CNM-Au8SALT LAKE CITY, Dec. 21, 2023 - Clene Inc. (Nasdaq: CLNN) and its subsidiary Clene Nanomedicine Inc., pioneers in the field of mitochondrial health and...

Capitalizing on decades of scientific research and technological advancements, Clene Inc., along with its wholly owned subsidiary Clene Nanomedicine Inc., has announced an exciting evolution in the fight against neurode...